Esophageal Carcinoma: Current Concepts in the Role of Imaging in Staging and Management

Tirumani, Harika; Rosenthal, Michael H.; Tirumani, Sree Harsha; Shinagare, Atul B.; Krajewski, Katherine M.; Ramaiya, Nikhil H.

doi:10.1016/j.carj.2014.08.006

Cited by 46 publications

(47 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 Before surgery, clinical staging should be performed to assess resectability with CT scan of the chest and abdomen, whole-body FDG-PET (integrated FDG-PET/CT scan is preferred), and EUS. 42 Esophagectomy should be considered for all medically fit patients with resectable esophageal cancer (.5 cm from cricopharyngeus). Cervical or cervicothoracic esophageal cancers ,5 cm from the cricopharyngeus should be treated with definitive chemoradiation.…”

Section: Principles Of Surgerymentioning

confidence: 99%

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Ajani

D’Amico

Bentrem

et al. 2019

Journal of the National Comprehensive Cancer Network

834

724

View full text Add to dashboard Cite

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

show abstract

Section: Principles Of Surgerymentioning

confidence: 99%

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Ajani

D’Amico

Bentrem

et al. 2019

Journal of the National Comprehensive Cancer Network

834

724

View full text Add to dashboard Cite

show abstract

“…Esophageal carcinoma is a common malignant tumor of digestive system with the mortality rate ranking the sixth in the world [1]. Surgical resection is preferred for patients with early esophageal cancer.…”

Section: Introductionmentioning

confidence: 99%

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma

Zhang

Yang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The morbidity and mortality of esophageal cancer is one of the highest around the world and the principal therapeutic method is radiation. Thus, searching for sensitizers with lower toxicity and higher efficiency to improve the efficacy of radiation therapy is critical essential. Our research group has previously reported that imetelstat, the thio-phosphoramidate oligonucleotide inhibitor of telomerase, can decrease cell proliferation and colony formation ability as well as increase DNA breaks induced by radiation in esophageal cancer cells. Further study in this project showed that imetelstat significantly sensitized esophageal cancer cells to radiation in vitro. Later study showed that imetelstat leads to increased cell apoptosis. We also measured the expression level of several DNA repair and apoptosis signaling proteins. pS345 CHK1, γ-H2AX, p53 and caspase3 expression were up-regulated in imetelstat treated cells, identifying these factors as molecular markers. Mouse in vivo model using imetelstat at clinically achievable concentrations and fractionated irradiation scheme yielded results demonstrating radiosensitization effect. Finally, TUNEL assay, caspase 3 and Ki67 staining in tumor tissue proved that imetelstat sensitized esophageal cancer to radiation in vivo through promoting cell apoptosis and inhibiting cell proliferation. Our study supported imetelstat increase radiation sensitivity of esophageal squamous cell carcinoma through inducing cell apoptosis and the specific inhibitor of telomerase might serve as a potential novel therapeutic tool for esophageal squamous cell carcinoma therapy.

show abstract

“…2 Pathological grade is highly determinant of patient prognosis; however, accurate preoperative grading of esophageal carcinoma has been extremely difficult by routine imaging modalities. [3][4][5][6] Endoscopy is widely employed to diagnose esophageal carcinoma and the differentiated grade can also be confirmed by biopsy, but it entails View this article online at wileyonlinelibrary.com.…”

mentioning

confidence: 99%

Esophageal carcinoma: Intravoxel incoherent motion diffusion‐weighted MRI parameters and histopathological correlations

Zhu

Gao

et al. 2018

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Esophageal Carcinoma: Current Concepts in the Role of Imaging in Staging and Management

Cited by 46 publications

References 34 publications

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma

Esophageal carcinoma: Intravoxel incoherent motion diffusion‐weighted MRI parameters and histopathological correlations

Contact Info

Product

Resources

About